Provexis PLC Result of AGM (5996S)
04 October 2017 - 2:10AM
UK Regulatory
TIDMPXS
RNS Number : 5996S
Provexis PLC
03 October 2017
3 October 2017
Provexis plc
Result of AGM
Provexis plc ('Provexis' or the 'Company'), the business that
develops, licenses and sells the proprietary, scientifically-proven
Fruitflow(R) heart-health functional food ingredient, is pleased to
announce that at the Annual General Meeting of the Company held
today all the resolutions were duly passed.
ends-
For further information please contact:
Provexis plc Tel: 07490 391888
Dawson Buck, Chairman enquiries@provexis.com
Ian Ford, Finance Director
Cenkos Securities plc Tel: 020 7397 8900
Bobbie Hilliam
Camilla Hume
Notes for editors
About Provexis plc
AIM-listed Provexis is focused on the development and licensing
of its proprietary, scientifically-proven Fruitflow(R) heart-health
functional food ingredient.
In May 2009, the Company's Fruitflow(R) technology was the first
to be substantiated by the European Food Safety Authority ('EFSA')
under the new Article 13(5) for proprietary and emerging science.
In December 2009 the European Commission authorised the health
claim 'Helps maintain normal platelet aggregation, which
contributes to healthy blood flow', which was the first wording to
be authorised under Article 13(5).
In June 2010 it was announced that the Company had entered into
a long-term Alliance Agreement with DSM Nutritional Products to
commercialise Fruitflow(R), and in June 2015 the Company confirmed
it had agreed significantly enhanced financial terms for its
Alliance Agreement with DSM for Fruitflow(R).
The Company's Alliance partner DSM Nutritional Products has
developed the market actively for the Company's novel, patented
Fruitflow(R) heart-health ingredient in all global markets, with
over 50 regional consumer healthcare brands now having been
launched by direct customers of DSM, and with a number of further
regional brands having been launched through DSM's distributor
channels.
An increasing number of further commercial projects have been
initiated by DSM with prospective customers, including some
prospective customers which are part of global businesses, with
good prospects for these projects to be launched as consumer
products. Interest in the technology exists in all major global
markets.
The Company reported in its preliminary results on 7 September
2017 that the Company and DSM had seen an encouraging increase in
brand awareness and customer interest in Fruitflow(R) in recent
months, with the total projected annual sales value of the
prospective sales pipeline for Fruitflow(R) continuing to increase
and standing at a new all-time high level.
In June 2016 the Company launched a high quality dietary
supplement product containing Fruitflow(R) and Omega-3 which is
being sold from a separate, dedicated website www.fruitflowplus.com
on a mail order basis.
The Company conducted a Key Opinion Leaders' roundtable event
for Fruitflow(R) in London in September 2016, focussed on raising
awareness of the importance of blood flow in cardiovascular health,
and the effectiveness of dietary antiplatelets. The roundtable was
attended by key scientists from Provexis and DSM, along with a
number of interested health care professionals with close links to
the media. The event was recorded and a video for Fruitflow(R) +
Omega-3 capsules targeting prospective consumers can be seen here
www.youtube.com/watch?v=P3HCSdyupEY&t=48s
The Company and DSM are keen to secure greater medical advocacy
for Fruitflow(R) and the roundtable event forms part of this
strategy.
The roundtable event is being supported by a broader consumer PR
campaign, and the Company's Fruitflow(R) + Omega-3 dietary
supplement product has featured in a number of recent articles in
the UK national press which can be seen here
www.fruitflowplus.com/fruitflow-in-the-media
The Company has been engaged in a two stage collaboration
agreement with the University of Oslo to undertake further research
into the relationship between Fruitflow(R) and blood pressure
regulation. In December 2016 the Company announced the results from
the second stage of the collaboration, a pilot study which
indicated that a standard dose of Fruitflow(R) in powder format
significantly lowered average 24-hour systolic blood pressure
compared to placebo. Both systolic and diastolic blood pressure
were shown to be significantly lower whilst trial subjects were
awake, a clinically relevant reduction in blood pressure which is
expected to be of interest to a large number of consumers and
patients with a wide range of cardiovascular conditions.
In April 2017 the Company announced it had entered into a
memorandum of understanding with BY-HEALTH Co., Ltd ('BY-HEALTH')
which is intended to result in a research and collaboration
agreement with BY-HEALTH for Fruitflow(R). The Company also
confirmed separately that Provexis and DSM are working with
BY-HEALTH to support the planned launch of some Fruitflow(R) based
products in the Chinese market, with the first launch envisaged in
the second half of 2017.
BY-HEALTH is a substantial Chinese listed dietary supplement
business which is currently valued in excess of GBP2bn.
Provexis was founded in 1999 and is headquartered in Reading,
Berkshire.
Provexis shares are traded on the AIM market of the London Stock
Exchange under the ticker symbol PXS.
For further information, please visit www.provexis.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGEXLFBDBFBFBV
(END) Dow Jones Newswires
October 03, 2017 11:10 ET (15:10 GMT)
Provexis (LSE:PXS)
Historical Stock Chart
From Apr 2024 to May 2024
Provexis (LSE:PXS)
Historical Stock Chart
From May 2023 to May 2024